Dialysis News and Research

Latest Dialysis News and Research

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

Ramipril can effectively reduce risk of ESRD in obese patients

The angiotensin-converting enzyme inhibitor drug, ramipril, is particularly effective in lowering the risk of end-stage renal disease in obese patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

29 Apr 2011

Five Loyola employees donate kidneys to complete strangers

Loyola University Medical Center is believed to be the first organization in the country, and perhaps the world, in which five employees have each donated kidneys to complete strangers with no strings attached.

28 Apr 2011

New discoveries on polycystin-1 can lead to novel kidney disease treatment

Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

27 Apr 2011

Studies emphasize need to avoid central venous catheters in patients on hemodialysis

Patients on peritoneal dialysis (PD) typically have a higher early survival rate than patients on hemodialysis (HD). New data suggest that this difference may be explained by a higher risk of early deaths among patients undergoing HD with central venous catheters, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

22 Apr 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

New biomarker-based test more effective for early acute kidney injury detection

A new biomarker-based diagnostic test is more effective than the current best practice for early detection of adverse outcomes after acute kidney injury, which can be fatal for an estimated 50 percent of the critically ill patients who get the condition.

19 Apr 2011

DaVita re-designs its leading online kidney disease resource

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, today announced the redesign and launch of DaVita.com, the leading online resource for information about kidney disease.

19 Apr 2011

Japan Tobacco and Torii commence ferric citrate Phase 3 clinical program for hyperphosphatemia

Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. (JT) and Torii Pharmaceutical Co., Ltd., JT's pharmaceutical business subsidiary, has commenced the Phase 3 clinical program of ferric citrate in Japan for the treatment of patients with hyperphosphatemia.

18 Apr 2011

ANNA releases new textbook on nephrology nurse's role

With the rate of chronic kidney disease in America spiking over the past two decades, the role of the nephrology nurse has become increasingly important as more lives are affected.

15 Apr 2011

Statin prior to major elective surgery can reduce serious kidney injury

Taking a statin before having major elective surgery reduces potentially serious kidney complications, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Apr 2011

Kidney transplantion more effective than previously thought

A new study from Mayo Clinic, the largest long-term study of kidney transplant recipients published to date, demonstrates that progressive damage to kidney transplants may be less common and less severe than previously reported.

8 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

AngioDynamics introduces DuraMax chronic dialysis catheter in the U.S.

AngioDynamics announced today the U.S. launch and initial shipments of the next generation DuraMax stepped-tip chronic dialysis catheter and the DuraMaxVP kit.

4 Apr 2011

KCP commends CMS for eliminating 'transition adjustment' imposed on new ESRD PPS

Kidney Care Partners, a broad-based coalition of patient advocates, dialysis professionals, care providers and manufacturers, commends the Centers for Medicare and Medicaid Services for eliminating the so-called "transition adjustment" imposed on dialysis facilities as part of the new Medicare end-stage renal disease prospective payment system.

2 Apr 2011

AngioScore launches AngioSculpt PTA Scoring Balloon Catheters for treatment of PAD

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of new, longer AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease.

1 Apr 2011

New CMS reimbursement system for ESRD may place cost constraints on clinics

According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011